Pfister Featured in HFMA on the Supreme Court ACA Ruling and its Impact on 340B

The state of the 340B program: What the Supreme Court’s Affordable Care Act ruling meant, and which issues still loom
– Healthcare Financial Management Association

Manatt Health Partner Helen Pfister spoke with the Healthcare Financial Management Association about the Supreme Court’s decision to not overturn the Affordable Care Act (ACA) and how it impacts the 340B Drug Pricing Program. In the article, Pfister stressed the importance of this decision for many 340B participants, saying, “if the Act had been overturned, then their eligibility would no longer exist and absent congressional action, they wouldn’t be able to participate in 340B anymore.” She also noted that there are three separate cases pending that may significantly impact the 340B program, and that regulatory updates could be considered also potentially impacting the program in the future.

Read the article here



pursuant to New York DR 2-101(f)

© 2022 Manatt, Phelps & Phillips, LLP.

All rights reserved